Jump to

Quality Control

Batch: Purity: 99.94%

99.94

Related Targets	HDAC PARP ATM/ATR DNA-PK WRN DNA/RNA Synthesis Topoisomerase PPAR Sirtuin Casein Kinase
Other ADC Cytotoxin Inhibitors	Triptolide SN-38 Luteolin (+)-Bicuculline Rutin Artemisinin BHQ Pinocembrin Luteoloside Lappaconite HBr

Cell Culture, Treatment & Working Concentration

Cell Lines	Assay Type	Incubation Time	Activity Description
LoVo	Cytotoxicity assay		Cytotoxicity against LoVo (human intestinal adenocarcinoma) cell line; Range 0.4-16 uM, IC50=16 μM
HL-60	Cytotoxicity assay		Cytotoxicity against HL-60 (human fibrosarcoma) cell line; Range 0.4-16 uM, IC50=16 μM
HT-29 cells	Cytotoxicity assay	96 h	Cytotoxicity against human HT-29 cells after 96 hrs by MTT assay, IC50=41.7 μM
HCT116 cells	Cytotoxicity assay	96 h	Cytotoxicity against human HCT116 cells after 96 hrs by MTT assay, IC50=45.6 μM
Click to View More Cell Line Experimental Data

Solubility

In vitro
Batch:

DMSO : 37 mg/mL (198.75 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	186.16	Formula	C₁₁H₆O₃	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	66-97-7	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	Psoralene, Ficusin, Furocoumarin			SMILES	C1=CC(=O)OC2=CC3=C(C=CO3)C=C21

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

In vitro	Psoralen inhibits the proliferation of MCF-7/ADR cells as shown by G0/G1 phase arrest rather than encouraging apoptosis. This compound reverses MDR(multidrug resistance) through inhibiting ATPase activity rather than reducing P-gp expression. It inhibits the migration abilities of MCF-7/ADR cells by repressing EMT possibly through inhibiting the activation of NF-κB. This chemical are photoactive compounds that readily alkylate DNA when activated by longwave ultraviolet light. Proliferation has been significantly promoted in MCF-7/ADR cells treated with low concentration of this compound (<10.75 µM) and inhibited with high concentration(>21.5 µM). It can inhibit metastasis of breast cancer. This compound mediates a variety of cell processes including cell death, proliferation, inflammation and migration.
In vivo	Psoralen has been characterized as a tumor suppressor in various tumors. This compound ameliorates sex hormone deficiency-induced osteoporosis in female and male mice. It has antiosteoporosis effect in ovariectomy-induced osteoporotic rats via stimulating osteoblastic differentiation from bone mesenchymal stem cells.
References	[1] https://pubmed.ncbi.nlm.nih.gov/26902225/ [2] https://www.hindawi.com/journals/bmri/2016/6869452/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-01-30)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04389281	RECRUITING	Advanced Solid Tumor Cancer	Immunolight, LLC	2021-12-08	PHASE1
NCT07055529	NOT_YET_RECRUITING	Vitiligo, Generalized	Hayat Abad Medical Complex, Peshawar	2026-06-01	EARLY_PHASE1
NCT01686594	COMPLETED	Patch/Plaque Stage Mycosis Fungoides	Medical University of Graz	2013-02	PHASE3
NCT01792245	UNKNOWN	Vitiligo	University of British Columbia	2013-02	PHASE2
NCT01732965	COMPLETED	Vitiligo	Henry Ford Health System	2013-03	PHASE4
NCT00724061	TERMINATED	Lymphoma	Northwestern University	2008-09

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Psoralen ADC Cytotoxin inhibitor

Chemical Structure

Molecular Weight: 186.16